{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:57:57Z","timestamp":1761541077883},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T00:00:00Z","timestamp":1326240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s11239-012-0680-3","type":"journal-article","created":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T07:43:02Z","timestamp":1326181382000},"page":"230-238","source":"Crossref","is-referenced-by-count":10,"title":["US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins"],"prefix":"10.1007","volume":"33","author":[{"given":"Marc","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter P.","family":"Jeske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose C.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawed","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,11]]},"reference":[{"key":"680_CR1","unstructured":"United States Food and Drug Administration (2010) Generic enoxaparin questions and answers. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm220037.htm . Accessed 9 Dec 2010"},{"key":"680_CR2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrd2307","volume":"6","author":"J Woodcock","year":"2007","unstructured":"Woodcock J, Griffin J, Behrman R et al (2007) The FDA\u2019s assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov 6:437\u2013442","journal-title":"Nat Rev Drug Discov"},{"key":"680_CR3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMp078095","volume":"357","author":"RG Frank","year":"2007","unstructured":"Frank RG (2007) Regulation of follow-on biologics. N Engl J Med 357:841\u2013843","journal-title":"N Engl J Med"},{"key":"680_CR4","volume-title":"Emerging health care issues: follow-on biologic drug competition","author":"Federal Trade Commission","year":"2009","unstructured":"Federal Trade Commission (2009) Emerging health care issues: follow-on biologic drug competition. Federal Trade Commission, Washington"},{"key":"680_CR5","unstructured":"So AD, Katz SL (2010) Biologics boondoggle. Op-Ed. New York Times 8 March 2010"},{"key":"680_CR6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMhle0706973","volume":"358","author":"DM Dudzinski","year":"2008","unstructured":"Dudzinski DM, Kesselheim AS (2008) Scientific and legal viability of follow-on protein drugs. N Engl J Med 358:843\u2013849","journal-title":"N Engl J Med"},{"key":"680_CR7","first-page":"i27","volume":"2","author":"H Schellekens","year":"2009","unstructured":"Schellekens H (2009) Biosimilar therapeutics\u2014what do we need to consider? Nephrol Dial Transplant Plus 2:i27\u2013i36","journal-title":"Nephrol Dial Transplant Plus"},{"key":"680_CR8","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1993.03510140024010","volume":"270","author":"SL Nightingale","year":"1993","unstructured":"Nightingale SL (1993) From the Food and Drug Administration. JAMA 270:1672","journal-title":"JAMA"},{"key":"680_CR9","first-page":"77","volume":"22","author":"J Fareed","year":"1996","unstructured":"Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM (1996) Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost 22:77\u201391","journal-title":"Semin Thromb Hemost"},{"key":"680_CR10","unstructured":"United States Food and Drug Administration (2010) Establishing active ingredient sameness for a generic enoxaparin sodium, a low molecular weight heparin. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm220023.htm . Accessed 9 Dec 2010"},{"key":"680_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2007-996063","volume":"23","author":"P Bianchini","year":"1997","unstructured":"Bianchini P, Liverani L, Mascellani G, Parma B (1997) Heterogeneity of unfractionated heparin studied in connection with species, source, and production processes. Semin Thromb Hemost 23:3\u201310","journal-title":"Semin Thromb Hemost"},{"key":"680_CR12","unstructured":"United States Food and Drug Administration (2010) Information on adverse event reports and heparin. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM112669 . Accessed 9 Dec 2010"},{"key":"680_CR13","unstructured":"United States Food and Drug Administration (2010) Countries with contaminated heparin API. http:\/\/www.fda.gov\/bbs\/topics\/news\/heparin\/heparinmaps.html . Accessed 9 Dec 2010"},{"key":"680_CR14","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa0803200","volume":"358","author":"TK Kishimoto","year":"2008","unstructured":"Kishimoto TK, Viswanathan K, Ganguly T et al (2008) Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358:2457\u20132467","journal-title":"N Engl J Med"},{"key":"680_CR15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-2007-996417","volume":"25","author":"RJ Linhardt","year":"1999","unstructured":"Linhardt RJ, Gunay NS (1999) Production and chemical processing of low molecular weight heparin. Semin Thromb Hemost 25:5\u201316","journal-title":"Semin Thromb Hemost"},{"key":"680_CR16","first-page":"1","volume":"2005","author":"P Bianchini","year":"2005","unstructured":"Bianchini P, Mascellani G (2005) Few bicyclic acetals at reducing end of low-molecular-weight heparins: might they restrict specification of pharmacopoeia? Pharmeur Sci Notes 2005:1\u20133","journal-title":"Pharmeur Sci Notes"},{"key":"680_CR17","volume-title":"Chemistry and biology of heparin and heparin sulphate","author":"MA Skidmore","year":"2005","unstructured":"Skidmore MA, Turnball JE (2005) Separation and sequencing of heparin and heparin sulphate saccharides. In: Garg H, Linhardt R, Hales C (eds) Chemistry and biology of heparin and heparin sulphate. Elsevier Press, NY"},{"key":"680_CR18","doi-asserted-by":"crossref","unstructured":"Jeske WP, Neville B, Ma Q, Hoppensteadt DA, Fareed J (2004) Effect of 1,6-anhdro bicyclic ring structure on the pharmacokinetic and pharmacodynamic behavior of low molecular weight heparin. Blood 104: A1868 (abstr)","DOI":"10.1182\/blood.V104.11.1868.1868"},{"key":"680_CR19","doi-asserted-by":"crossref","unstructured":"Jeske W, Vandenberg C, Maddineni J, Florian M, Hoppensteadt D, Walenga JM (2006) Are generic LMWHs equivalent to the innovator products? FASEB J 20: A654 (abstr)","DOI":"10.1096\/fasebj.20.4.A654-a"},{"key":"680_CR20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-2008-1066026","volume":"34","author":"WP Jeske","year":"2008","unstructured":"Jeske WP, Walenga JM, Hoppensteadt DA et al (2008) Differentiating low-molecular-weight heparins based on chemical, biological and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost 34:74\u201385","journal-title":"Semin Thromb Hemost"},{"key":"680_CR21","unstructured":"Walenga J, Jeske W, Hoppensteadt D et al (2008) Differential heparin-induced thrombocytopenic potential of low molecular weight heparins. Int Angiol 27: 26 (abstr)"},{"key":"680_CR22","doi-asserted-by":"crossref","unstructured":"Gomes M, Ramacciotti E, Hoppensteadt D et al (2010) An open label, non randomized, prospective phase IV clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilar in healthy volunteers. ASH 1086 (abstr)","DOI":"10.1182\/blood.V116.21.1086.1086"},{"key":"680_CR23","unstructured":"European Medicines Agency (2009) Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins. European Medicines Agency Committee for Medicinal Products for Human Use, London, pp 1\u20137"},{"key":"680_CR24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","volume":"337","author":"M Cohen","year":"1997","unstructured":"Cohen M, Demers C, Gurfinkel EP et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 337:447\u2013452","journal-title":"N Engl J Med"},{"key":"680_CR25","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","volume":"354","author":"EM Antman","year":"2006","unstructured":"Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477\u20131488","journal-title":"N Engl J Med"},{"key":"680_CR26","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJMoa052711","volume":"355","author":"G Montalescot","year":"2006","unstructured":"Montalescot G, White HD, Gallo R et al (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355:1006\u20131017","journal-title":"N Engl J Med"},{"key":"680_CR27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FJC.0b013e3181a59abc","volume":"53","author":"JC Nicolau","year":"2009","unstructured":"Nicolau JC, Cohen M, Montalescot G (2009) Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes. J Cardiovasc Pharmacol 53:440\u2013445","journal-title":"J Cardiovasc Pharmacol"},{"key":"680_CR28","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0002-8703(03)00179-0","volume":"146","author":"LK Michalis","year":"2003","unstructured":"Michalis LK, Katsouras CS, Papamichael N et al (2003) Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 146:304\u2013310","journal-title":"Am Heart J"},{"key":"680_CR29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ahj.2004.09.028","volume":"150","author":"C Katsouras","year":"2005","unstructured":"Katsouras C, Michalis LK, Papamichael N et al (2005) Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6\u00a0months. Am Heart J 150:385\u2013391","journal-title":"Am Heart J"},{"key":"680_CR30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0002-9149(03)00105-X","volume":"91","author":"G Montalescot","year":"2003","unstructured":"Montalescot G, Bal-dit-Sollier C, Chibedi D et al (2003) Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol 91:925\u2013930","journal-title":"Am J Cardiol"},{"key":"680_CR31","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIR.0b013e31822d97d5","volume":"124","author":"DR Holmes Jr","year":"2011","unstructured":"Holmes DR Jr, Becker JA, Limacher MC, Granger CB, Page RL, Sila C (2011) ACCF\/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. Circulation 124:1290\u20131310","journal-title":"Circulation"},{"key":"680_CR32","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMp1112633","volume":"365","author":"BA Chabner","year":"2011","unstructured":"Chabner BA (2011) Drug shortages\u2014a critical challenge for the generic-drug market. N Engl J Med 365:2147\u20132149","journal-title":"N Engl J Med"},{"key":"680_CR33","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMp1109772","volume":"365","author":"ML Gatesman","year":"2011","unstructured":"Gatesman ML, Smith TJ (2011) The shortages of essential chemotherapy drugs in the United States. N Engl J Med 365:1653\u20131655","journal-title":"N Engl J Med"},{"key":"680_CR34","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMp1005849","volume":"363","author":"V Jensen","year":"2010","unstructured":"Jensen V, Rappaport BA (2010) The reality of drug shortages\u2014the case of the injectable agent propofol. N Engl J Med 363:806\u2013807","journal-title":"N Engl J Med"},{"key":"680_CR35","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMp1006189","volume":"363","author":"NK Choudhry","year":"2010","unstructured":"Choudhry NK, Shrank WH (2010) Four-dollar generics\u2014Increased accessibility, impaired quality assurance. N Engl J Med 363:1885\u20131887","journal-title":"N Engl J Med"},{"key":"680_CR36","unstructured":"French Cardiovascular Society (2010) Communiqu\u00e9\u2013Clopidogrel: des g\u00e9n\u00e9riques retir\u00e9s du march\u00e9! http:\/\/www.cardio-sfc.org\/activites\/informations\/communiques-de-la-sfc\/en-direct-de-la-sfc-2\/communique-clopidogrel-des-generiques-retires-du-marche\/ . Accessed 9 Dec 2010"},{"key":"680_CR37","unstructured":"Nicolas A (2010) Les g\u00e9n\u00e9riques sont-ils de bons m\u00e9dicaments? http:\/\/www.lefigaro.fr\/sante\/2010\/06\/20\/01004-20100620ARTFIG00224-les-generiques-sont-ils-de-bons-medicaments.php . Accessed 9 Dec 2010"},{"key":"680_CR38","unstructured":"Villel\u00e9ger JP (2010) Les m\u00e9dicaments g\u00e9n\u00e9riques sont-ils fiables? http:\/\/www.lemonde.fr\/idees\/chronique\/2010\/10\/17\/les-medicaments-generiques-sont-ils-fiables_1427013_3232.html . Accessed 9 Dec 2010"},{"key":"680_CR39","unstructured":"European Medicines Agency (2010) European Medicines Agency recommends precautionary recall of batches of clopidogrel-containing medicines from Acino Pharma GmbH. EMA, London"},{"key":"680_CR40","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMsa1007467","volume":"363","author":"MA Hamburg","year":"2010","unstructured":"Hamburg MA (2010) Innovation, regulation and the FDA. N Engl J Med 363:2228\u20132232","journal-title":"N Engl J Med"},{"key":"680_CR41","unstructured":"United States Food and Drug Administration. Warning Letters 1997\u20132010 [United States Food and Drug Administration Website]. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/EnforcementActivitiesbyFDA\/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies\/default.htm . Accessed 9 Dec 2010"},{"key":"680_CR42","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMsb055203","volume":"355","author":"AJJ Wood","year":"2006","unstructured":"Wood AJJ (2006) A proposal for radical changes in the drug-approval process. NEJM 355:618\u2013623","journal-title":"NEJM"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-012-0680-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-012-0680-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-012-0680-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T15:54:18Z","timestamp":1640447658000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-012-0680-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,11]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["680"],"URL":"https:\/\/doi.org\/10.1007\/s11239-012-0680-3","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,11]]}}}